Wegovy vs Mounjaro: Which Is More Effective for Weight Management?

Last medically reviewed: March 2026

Quick Summary:

• Wegovy (semaglutide) and Mounjaro (tirzepatide) are injectable medications approved for weight management.
• Both drugs mimic gut hormones to regulate appetite, but Mounjaro targets two hormones (GIP and GLP-1) versus Wegovy targeting one (GLP-1).
• Clinical evidence from recent trials shows Mounjaro generally achieves greater average weight loss than Wegovy.
• NHS guidelines recommend pharmacotherapy as part of a comprehensive weight management programme, focusing on lifestyle changes alongside medication.
• Side effect profiles are broadly similar, with gastrointestinal symptoms being most common.
• Cost, availability, and personal response may influence treatment choice; always consult your healthcare provider before starting therapy.

Obesity remains one of the UK’s most pressing public health challenges, with significant implications for chronic diseases such as type 2 diabetes and cardiovascular conditions. In recent years, advancements in pharmacotherapy have revolutionised weight management options, particularly with injectable medicines like Wegovy and Mounjaro gaining attention. Many of our readers ask: “Wegovy vs Mounjaro – which is more effective?”

In this comprehensive article, we explore the mechanisms, clinical trial data, side effects, cost considerations, and guidance from UK health authorities to provide an evidence-based comparison tailored to those considering pharmacological options for weight loss.

Understanding the Basics: What Are Wegovy and Mounjaro?

Wegovy (Semaglutide)

Wegovy is the brand name for semaglutide at a higher dose, a glucagon-like peptide-1 (GLP-1) receptor agonist. Originally developed for type 2 diabetes, it was later approved for chronic weight management in adults with a body mass index (BMI) ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities.

According to the NICE guidance, Wegovy is administered via once-weekly subcutaneous injections starting at 0.25mg weekly and titrated up to a maintenance dose of 2.4mg weekly.

Mounjaro (Tirzepatide)

Mounjaro is a newer injectable medication approved in the UK in 2024, which acts as a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. This dual action aims to enhance insulin sensitivity and appetite suppression more effectively than GLP-1 alone.

The dosing regimen typically starts at 2.5mg weekly, increasing to a maintenance dose ranging from 7.5mg to 15mg weekly depending on tolerance and efficacy.

How Do Their Mechanisms of Action Differ?

GLP-1 Receptor Agonism

Both Wegovy and Mounjaro stimulate GLP-1 receptors, which enhance insulin secretion, delay gastric emptying, and reduce appetite through central nervous system pathways. GLP-1 also promotes satiety and reduces caloric intake.

Dual Agonism of GIP and GLP-1 by Mounjaro

Mounjaro’s unique feature is its activation of GIP receptors alongside GLP-1 receptors. GIP plays a role in enhancing insulin secretion and may improve fat metabolism and energy expenditure. Some clinical evidence suggests this dual agonism leads to more profound weight loss and improved glycaemic control.

Clinical Effectiveness: What Does the Evidence Say?

To determine which is more effective, it is essential to review the latest clinical trials, especially those comparing average weight loss outcomes, safety, and tolerability.

Wegovy Clinical Trials

The STEP (Semaglutide Treatment Effect in People with obesity) clinical trial programme informs much of the current understanding of Wegovy’s efficacy. According to a 2025 study published in The Lancet Diabetes & Endocrinology, participants receiving 2.4mg weekly experienced an average weight loss of approximately 15% of their initial body weight over 68 weeks compared to placebo.

Mounjaro Clinical Trials

The SURMOUNT series of trials evaluated Mounjaro for obesity management. In SURMOUNT-1, a 2025 trial published in The New England Journal of Medicine, participants achieved up to 22.5% mean weight loss at the highest dose (15mg) over 72 weeks, substantially exceeding placebo and Wegovy results.

Direct Comparisons

Though head-to-head comparisons in large-scale UK-based trials remain limited, indirect meta-analyses indicate that Mounjaro may provide superior weight loss benefits compared to Wegovy, albeit with a similar side effect profile.

Feature	Wegovy (Semaglutide)	Mounjaro (Tirzepatide)
Mechanism	GLP-1 receptor agonist	Dual GIP and GLP-1 receptor agonist
Administration	Once-weekly injection, 0.25mg to 2.4mg	Once-weekly injection, 2.5mg to 15mg
Average Weight Loss	~15% over 68 weeks (STEP trials)	Up to 22.5% over 72 weeks (SURMOUNT trials)
Common Side Effects	Nausea, vomiting, diarrhoea	Nausea, vomiting, diarrhoea
NHS Approval for Weight Management	Yes; prescribed as part of supervised programmes	Approved in 2024; increasing use in specialised centres
Cost (approximate UK private price)	£300-£350 per month	£350-£400 per month

Safety and Side Effects Profile

Gastrointestinal Effects

Both drugs commonly cause gastrointestinal side effects such as nausea, diarrhoea, constipation, and vomiting, especially during dose escalation. These tend to be mild to moderate and often resolve after a few weeks.

Other Considerations

Rare but serious risks include pancreatitis and gallbladder disease. According to NHS guidance, patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should avoid GLP-1 receptor agonists like Wegovy. Similar precautions apply to Mounjaro.

Cost and Accessibility in the UK

Currently, both Wegovy and Mounjaro are high-cost medications not routinely commissioned by the NHS for weight management, but access may be available through specialist obesity clinics or private prescriptions.

Private costs range from approximately £300 to over £400 per month depending on dosage, pharmacy, and patient support programmes. NHS England is reviewing broader access following promising clinical outcomes.

Patient Suitability and Practical Considerations

Who Should Consider Wegovy?

Patients with BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities such as hypertension or type 2 diabetes may benefit according to NICE criteria. Wegovy is well-suited for those who tolerate GLP-1 agonists and seek moderate to substantial weight loss.

Who is Mounjaro Best For?

Mounjaro may be preferable for patients with type 2 diabetes and obesity, especially if greater weight loss and glycaemic control are desired. However, long-term real-world data in the UK population is still emerging.

Practical Tips for Use

• Both require refrigeration and subcutaneous injection training.
• Regular follow-up with healthcare providers for dose adjustments and monitoring is essential.
• Lifestyle changes (diet, physical activity) remain cornerstone treatments alongside pharmacotherapy.

Frequently Asked Questions

1. Are Wegovy and Mounjaro approved by the NHS?

Currently, both are not routinely available on the NHS for weight loss, but can be prescribed privately or via specialist centres. NHS guidelines encourage using pharmacotherapy as part of a comprehensive weight management programme.

2. Which medication causes more side effects?

Both have similar gastrointestinal side effects, but Mounjaro’s dual agonism may lead to slightly higher nausea rates during dose escalation. Side effects usually subside over time.

3. Can these medications be used together?

No. Due to overlapping mechanisms, combining Wegovy and Mounjaro is not recommended and may increase adverse effects.

4. How long does it take to see weight loss results?

Most patients notice weight loss within 4-12 weeks of starting therapy, with maximum effects typically observed after 68 to 72 weeks.

5. Are there any dietary restrictions when taking these drugs?

There are no strict dietary restrictions, but following a balanced calorie-controlled diet enhances effectiveness and reduces gastrointestinal discomfort.

6. Is one medication better for people with type 2 diabetes?

Mounjaro has demonstrated superior glycaemic control compared to Wegovy and may be preferred for patients with type 2 diabetes and obesity.

Conclusion: Which Is More Effective – Wegovy or Mounjaro?

In our experience reviewing the latest clinical evidence and NHS guidelines, both Wegovy and Mounjaro represent significant advances in obesity pharmacotherapy. Clinical trials consistently show Mounjaro delivers greater average weight loss, particularly at higher doses, likely due to its dual hormone receptor activity.

However, the choice between Wegovy and Mounjaro should be individualised, taking into account patient medical history, comorbidities, side effect tolerance, cost, and availability. NHS guidelines recommend that these medications are prescribed as part of multidisciplinary weight management programmes including dietary, physical activity, and behavioural support.

If you are considering these options, consult your GP or a registered healthcare professional specialising in obesity management. They can help determine the most appropriate and safe treatment plan tailored to your needs.

Actionable Recommendations

• Consult your healthcare provider before starting any treatment.
• Combine medication with lifestyle interventions for optimal results.
• Report any side effects promptly to ensure safety.
• Explore specialist obesity services for comprehensive support.
• Stay informed about evolving NHS policies regarding access to these medications.

---

About the Author

Dr Emily Carter BSc Nutrition, MSc Pharmacology, Registered Nutritionist, is a UK-based health professional specialising in nutritional science and pharmacological treatments for metabolic disorders. She has over 10 years’ experience writing evidence-based health content for NHS-affiliated publications and patient education centres.